On November 14th, 2017, Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) announced the launch of ImminAG™, the first non-cannabis CBD product on the market. The time-released product is derived from the hops plant and was unveiled at the Marijuana Business Conference and Expo (MJBizCon) in Las Vegas, and will be available for purchase through Isodiol’s website.

Marcos Agramont, CEO of Isodiol, said “The release of ImmunAG is a monumental milestone for Isodiol, as it marks the industry’s first foray into non-cannabis CBD products… This launch is a continuation of our company strategy to provide a diverse range of products as we strive to increase shareholder value by creating entirely new market segments.”

Isodiol International Inc. is a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products. Isodiol is the pioneer of many firsts for the cannabis industry, including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.